Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays critical roles in cell cycling and DNA damage response. Overexpression of PLK1 is associated with the poorer prognosis of cancers, including colorectal cancer (CRC). Although the downstream pathways of the overexpression that lead to oncogenesis have been extensively studied, little is known about the factors that cause the overexpression of PLK1 in CRC. DNA methylation was reported to be affecting the expression of PLK1 in some cancers. The study aims to investigate the contribution of genetic mutation and DNA methylation of the PLK1 gene to the overexpression of PLK1 in CRC. The study involves data mining from Catalogue of Somatic Mutations in Cancer (COSMIC) and UniProtKB, Sanger sequencing on DNA from the cell lines HCT116, SW48, Colo320DM and T84 to analyse the possible mutation of PLK1. Other than that methylation status of the PLK1 promoter in CRC are also analysed by using mass spectrometry (MS) and pyrosequencing. Data from the COSMIC show the low incidences of PLK1 mutation for CRC (3.02%) with 46 mutations identified. One of the mutation p.R337Q (c.1010G > A) is located in the D-box which is an important motif for protein ubiquitination and eventually proteasomal degradation. Hence this mutation may potentially result in stabilisation of the PLK1 protein. Mutations are detected at the upstream silencer region, the promoter region and Exon1 in HCT116 but are not located at the protein binding or functioning site. Similarly, the same mutation at promoter region is detected in SW48. Differential trends of changes in methylation status of PLK1 in the IR treated CRC cell lines detected by MS reveal the possible association between the methylation and the radiosensitivity. Furthermore, pyrosequencing shows that PLK1 methylation status in tumour tissues with high expression of PLK1 is not significantly different from those with no PLK1 expression. In conclusion, mutation of PLK1 gene is infrequent in CRC and the expression of PLK1 is unlikely to be dependent on DNA methylation in the promoter region of PLK1 in the CRC.
References
[1]
Archambault, V. and Glover, D.M. (2009) Polo-Like Kinases: Conservation and Divergence in Their Functions and Regulation. Nature Reviews Molecular Cell Biology, 10, 265-275. https://doi.org/10.1038/nrm2653
[2]
Takai, N., Hamanaka, R., Yoshimatsu, J. and Miyakawa, I. (2005) Polo-Like Kinases (Plks) and Cancer. Oncogene, 24, 287-291. https://doi.org/10.1038/sj.onc.1208272
[3]
Tut, T.G., Lim, S.H., Dissanayake, I.U., Descallar, J., Chua, W., Ng, W., de Souza, P., Shin, J.S. and Lee, C.S. (2015) Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PLoS ONE, 10, 1-11.
https://doi.org/10.1371/journal.pone.0129313
[4]
Palmisiano, N.D. and Kasner, M.T. (2015) Polo-Like Kinase and Its Inhibitors: Ready for the Match to Start? American Journal of Hematology, 90, 1071-1076.
https://doi.org/10.1002/ajh.24177
[5]
Chopra, P., Sethi, G., Dastidar, S.G. and Ray, A. (2010) Polo-Like Kinase Inhibitors: An Emerging Opportunity for Cancer Therapeutics. Expert Opinion on Investigational Drugs, 19, 27-43. https://doi.org/10.1517/13543780903483191
[6]
Yim, H. (2013) Current Clinical Trials with Polo-Like Kinase 1 Inhibitors in Solid Tumors. Anticancer Drugs, 24, 999-1006.
https://doi.org/10.1097/CAD.0000000000000007
[7]
Strebhardt, K. (2010) Multifaceted Polo-Like Kinases: Drug Targets and Antitargets for Cancer Therapy. Nature Reviews Drug Discovery, 9, 643-660.
https://doi.org/10.1038/nrd3184
[8]
Rodel, F., Keppner, S., Capalbo, G., Bashary, R., Kaufmann, M., Rodel, C., Strebhardt, K. and Spankuch, B. (2010) Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer. American Journal of Pathology, 177, 918-929. https://doi.org/10.2353/ajpath.2010.100040
[9]
Cebrian, A., Gomez Del Pulgar, T., Fernandez-Acenero, M.J., Borrero-Palacios, A., Del Puerto-Nevado, L., Martinez-Useros, J., Marin-Arango, J.P., Carames, C., Vega-Bravo, R., Rodriguez-Remirez, M., Manzarbeitia, F. and Garcia-Foncillas, J. (2016) Decreased PLK1 Expression Denotes Therapy Resistance and Unfavourable Disease-Free Survival in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Pathology—Research and Practice, 212, 1133-1137.
https://doi.org/10.1016/j.prp.2016.09.012
[10]
Martin, B.T. and Strebhardt, K. (2006) Polo-Like Kinase 1: Target and Regulator of Transcriptional Control. Cell Cycle, 5, 2881-2885.
https://doi.org/10.4161/cc.5.24.3538
[11]
Alvarez, B., Martinez, A.C., Burgering, B.M. and Carrera, A.C. (2001) Forkhead Transcription Factors Contribute to Execution of the Mitotic Programme in Mammals. Nature, 413, 744-747. https://doi.org/10.1038/35099574
[12]
Uchiumi, T., Longo, D.L. and Ferris, D.K. (1997) Cell Cycle Regulation of the Human Polo-Like Kinase (PLK) Promoter. Journal of Biological Chemistry, 272, 9166-9174. https://doi.org/10.1074/jbc.272.14.9166
[13]
Tategu, M., Nakagawa, H., Sasaki, K., Yamauchi, R., Sekimachi, S., Suita, Y., Watanabe, N. and Yoshid, K. (2008) Transcriptional Regulation of Human Polo-Like Kinases and Early Mitotic Inhibitor. Journal of Genetics and Genomics, 35, 215-224. https://doi.org/10.1016/S1673-8527(08)60030-2
[14]
Simizu, S. and Osada, H. (2000) Mutations in the Plk Gene Lead to Instability of Plk Protein in Human Tumour Cell Lines. Nature Cell Biology, 2, 852-854.
https://doi.org/10.1038/35041102
[15]
Ward, A., Morettin, A., Shum, D. and Hudson, J.W. (2011) Aberrant Methylation of Polo-Like Kinase CpG Islands in Plk4 Heterozygous Mice. BMC Cancer, 11, 71.
https://doi.org/10.1186/1471-2407-11-71
[16]
Ward, A., Sivakumar, G., Kanjeekal, S., Hamm, C., Labute, B.C., Shum, D. and Hudson, J.W. (2015) The Deregulated Promoter Methylation of the Polo-Like Kinases as a Potential Biomarker in Hematological Malignancies. Leukemia & lymphoma, 56, 2123-2133. https://doi.org/10.3109/10428194.2014.971407
[17]
Antwih, D.A., Gabbara, K.M., Lancaster, W.D., Ruden, D.M. and Zielske, S.P. (2013) Radiation-Induced Epigenetic DNA Methylation Modification of Radiation-Response Pathways. Epigenetics, 8, 839-848. https://doi.org/10.4161/epi.25498
[18]
Forbes, S.A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C.G., Ward, S., Dawson, E., Ponting, L., Stefancsik, R., Harsha, B., Kok, C.Y., Jia, M., Jubb, H., Sondka, Z., Thompson, S., De, T. and Campbell, P.J. (2017) COSMIC: Somatic Cancer Genetics at High-Resolution. Nucleic Acids Research, 45, 777-783.
https://doi.org/10.1093/nar/gkw1121
[19]
Oliveira, C., Pinto, M., Duval, A., Brennetot, C., Domingo, E., Espin, E., Armengol, M., Yamamoto, H., Hamelin, R., Seruca, R. and Schwartz Jr, S. (2003) BRAF Mutations Characterize Colon but Not Gastric Cancer with Mismatch Repair Deficiency. Oncogene, 22, 9192-9196. https://doi.org/10.1038/sj.onc.1207061
[20]
Ahmed, D., Eide, P.W., Eilertsen, I.A., Danielsen, S.A., Eknaes, M., Hektoen, M., Lind, G.E. and Lothe, R.A. (2013) Epigenetic and Genetic Features of 24 Colon Cancer Cell Lines. Oncogenesis, 2, e71. https://doi.org/10.1038/oncsis.2013.35
[21]
Dunne, A.L., Price, M.E., Mothersill, C., McKeown, S.R., Robson, T. and Hirst, D.G. (2003) Relationship between Clonogenic Radiosensitivity, Radiation-Induced Apoptosis and DNA Damage/Repair in Human Colon Cancer Cells. British Journal of Cancer, 89, 2277-2283. https://doi.org/10.1038/sj.bjc.6601427
[22]
Amundson, S.A., Do, K.T., Vinikoor, L.C., Lee, R.A., Koch-Paiz, C.A., Ahn, J., Reimers, M., Chen, Y., Scudiero, D.A., Weinstein, J.N., Trent, J.M., Bittner, M.L., Meltzer, P.S. and Fornace Jr, A.J. (2008) Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen. Cancer Research, 68, 415-424.
https://doi.org/10.1158/0008-5472.CAN-07-2120
[23]
Frykholm, G., Glimelius, B., Richter, S. and Carlsson, J. (1991) Heterogeneity in Antigenic Expression and Radiosensitivity in Human Colon Carcinoma Cell Lines. In Vitro Cellular & Developmental Biology, 27, 900-906.
https://doi.org/10.1007/BF02631115
[24]
Wang, Q., Wang, Y., Du, L., Xu, C., Sun, Y., Yang, B., Sun, Z., Fu, Y., Cai, L., Fan, S., Fan, F. and Liu, Q. (2014) shRNA-Mediated XRCC2 Gene Knockdown Efficiently Sensitizes Colon Tumor Cells to X-Ray Irradiation in Vitro and in Vivo. International Journal of Molecular Sciences, 15, 2157-2171.
https://doi.org/10.3390/ijms15022157
[25]
Akdeli, N., Riemann, K., Westphal, J., Hess, J., Siffert, W. and Bachmann, H.S. (2014) A 3'UTR Polymorphism Modulates mRNA Stability of the Oncogene and Drug Target Polo-Like Kinase 1. Molecular Cancer, 13, 87.
https://doi.org/10.1186/1476-4598-13-87
[26]
The UniProt Consortium (2017) UniProt: The Universal Protein Knowledgebase. Nucleic Acids Research, 45, D158-D169. https://doi.org/10.1093/nar/gkw1099
[27]
Shin, J.S., Tut, T.G., Yang, T. and Lee, C.S. (2013) Radiotherapy Response in Microsatellite Instability Related Rectal Cancer. The Korean Journal of Pathology, 47, 1-8. https://doi.org/10.4132/KoreanJPathol.2013.47.1.1
[28]
Lindon, C. and Pines, J. (2004) Ordered Proteolysis in Anaphase Inactivates Plk1 to Contribute to Proper Mitotic Exit in Human Cells. Journal of Cell Biology, 164, 233-241. https://doi.org/10.1083/jcb.200309035
[29]
Pogribny, I., Koturbash, I., Tryndyak, V., Hudson, D., Stevenson, S.M., Sedelnikova, O., Bonner, W. and Kovalchuk, O. (2005) Fractionated Low-Dose Radiation Exposure Leads to Accumulation of DNA Damage and Profound Alterations in DNA and Histone Methylation in the Murine Thymus. Molecular Cancer Research, 3, 553-561. https://doi.org/10.1158/1541-7786.MCR-05-0074
[30]
Zielske, S.P. (2015) Epigenetic DNA Methylation in Radiation Biology: On the Field or on the Sidelines? Journal of Cellular Biochemistry, 116, 212-217.
https://doi.org/10.1002/jcb.24959
